Accelerated atherosclerosis in rheumatoid arthritis

Z. Szekanecz, G. Kerekes, H. Dér, Zsuzsa Sándor, Z. Szabó, A. Végvári, Enikö Simkovics, Lilla Soós, Ágnes Szentpétery, Timea Besenyei, G. Szűcs, S. Szántó, László Tamási, G. Szegedi, Yehuda Shoenfeld, P. Soltész

Research output: Chapter in Book/Report/Conference proceedingConference contribution

90 Citations (Scopus)

Abstract

Cardiovascular disease is a leading cause of mortality in rheumatoid arthritis (RA). Endothelial dysfunction often precedes manifest atherosclerosis. Both traditional, Framingham risk factors and inflammation-associated factors are involved in RA-associated atherosclerosis. Among imaging techniques, the early determination of common carotid intima-media thickness (ccIMT), flow-mediated vasodilation (FMD), and nitroglycerine-mediated vasodilation (NMD) may be useful to determine atherosclerosis and endothelial dysfunction.We and others found increased ccIMT and impaired FMD in RA patients. Among immunological and metabolic laboratory markers, anticyclic citrullinated peptide (anti-CCP) antibodies, IgM rheumatoid factor, circulating immune complexes, pro-inflammatory cytokines including tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), Th0/Th1Tcells, homocysteine, dyslipidemia, decreased folate and vitamin B12 production, and impaired paraoxonase activity may all be involved in the development of vascular disease in RA. The early diagnosis of endothelial dysfunction and atherosclerosis, active immunosuppressive treatment, the use of drugs that control atherosclerosis, changes in sedentary lifestyle, and the close follow-up of RA patients may help to minimize cardiovascular risk in these individuals.

Original languageEnglish
Title of host publicationAnnals of the New York Academy of Sciences
Pages349-358
Number of pages10
Volume1108
DOIs
Publication statusPublished - Jun 2007

Publication series

NameAnnals of the New York Academy of Sciences
Volume1108
ISSN (Print)00778923
ISSN (Electronic)17496632

Fingerprint

Rheumatoid Arthritis
Atherosclerosis
Vasodilation
Carotid Intima-Media Thickness
Aryldialkylphosphatase
Rheumatoid Factor
Nitroglycerin
Homocysteine
Vitamin B 12
Immunosuppressive Agents
Antigen-Antibody Complex
Folic Acid
Immunoglobulin M
Interleukin-6
Sedentary Lifestyle
Tumor Necrosis Factor-alpha
Cytokines
Drug and Narcotic Control
Imaging techniques
Dyslipidemias

Keywords

  • Atherosclerosis
  • Endothelial dysfunction
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Szekanecz, Z., Kerekes, G., Dér, H., Sándor, Z., Szabó, Z., Végvári, A., ... Soltész, P. (2007). Accelerated atherosclerosis in rheumatoid arthritis. In Annals of the New York Academy of Sciences (Vol. 1108, pp. 349-358). (Annals of the New York Academy of Sciences; Vol. 1108). https://doi.org/10.1196/annals.1422.036

Accelerated atherosclerosis in rheumatoid arthritis. / Szekanecz, Z.; Kerekes, G.; Dér, H.; Sándor, Zsuzsa; Szabó, Z.; Végvári, A.; Simkovics, Enikö; Soós, Lilla; Szentpétery, Ágnes; Besenyei, Timea; Szűcs, G.; Szántó, S.; Tamási, László; Szegedi, G.; Shoenfeld, Yehuda; Soltész, P.

Annals of the New York Academy of Sciences. Vol. 1108 2007. p. 349-358 (Annals of the New York Academy of Sciences; Vol. 1108).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Szekanecz, Z, Kerekes, G, Dér, H, Sándor, Z, Szabó, Z, Végvári, A, Simkovics, E, Soós, L, Szentpétery, Á, Besenyei, T, Szűcs, G, Szántó, S, Tamási, L, Szegedi, G, Shoenfeld, Y & Soltész, P 2007, Accelerated atherosclerosis in rheumatoid arthritis. in Annals of the New York Academy of Sciences. vol. 1108, Annals of the New York Academy of Sciences, vol. 1108, pp. 349-358. https://doi.org/10.1196/annals.1422.036
Szekanecz Z, Kerekes G, Dér H, Sándor Z, Szabó Z, Végvári A et al. Accelerated atherosclerosis in rheumatoid arthritis. In Annals of the New York Academy of Sciences. Vol. 1108. 2007. p. 349-358. (Annals of the New York Academy of Sciences). https://doi.org/10.1196/annals.1422.036
Szekanecz, Z. ; Kerekes, G. ; Dér, H. ; Sándor, Zsuzsa ; Szabó, Z. ; Végvári, A. ; Simkovics, Enikö ; Soós, Lilla ; Szentpétery, Ágnes ; Besenyei, Timea ; Szűcs, G. ; Szántó, S. ; Tamási, László ; Szegedi, G. ; Shoenfeld, Yehuda ; Soltész, P. / Accelerated atherosclerosis in rheumatoid arthritis. Annals of the New York Academy of Sciences. Vol. 1108 2007. pp. 349-358 (Annals of the New York Academy of Sciences).
@inproceedings{166f96a758dc4488889d695dc36a27d4,
title = "Accelerated atherosclerosis in rheumatoid arthritis",
abstract = "Cardiovascular disease is a leading cause of mortality in rheumatoid arthritis (RA). Endothelial dysfunction often precedes manifest atherosclerosis. Both traditional, Framingham risk factors and inflammation-associated factors are involved in RA-associated atherosclerosis. Among imaging techniques, the early determination of common carotid intima-media thickness (ccIMT), flow-mediated vasodilation (FMD), and nitroglycerine-mediated vasodilation (NMD) may be useful to determine atherosclerosis and endothelial dysfunction.We and others found increased ccIMT and impaired FMD in RA patients. Among immunological and metabolic laboratory markers, anticyclic citrullinated peptide (anti-CCP) antibodies, IgM rheumatoid factor, circulating immune complexes, pro-inflammatory cytokines including tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), Th0/Th1Tcells, homocysteine, dyslipidemia, decreased folate and vitamin B12 production, and impaired paraoxonase activity may all be involved in the development of vascular disease in RA. The early diagnosis of endothelial dysfunction and atherosclerosis, active immunosuppressive treatment, the use of drugs that control atherosclerosis, changes in sedentary lifestyle, and the close follow-up of RA patients may help to minimize cardiovascular risk in these individuals.",
keywords = "Atherosclerosis, Endothelial dysfunction, Rheumatoid arthritis",
author = "Z. Szekanecz and G. Kerekes and H. D{\'e}r and Zsuzsa S{\'a}ndor and Z. Szab{\'o} and A. V{\'e}gv{\'a}ri and Enik{\"o} Simkovics and Lilla So{\'o}s and {\'A}gnes Szentp{\'e}tery and Timea Besenyei and G. Szűcs and S. Sz{\'a}nt{\'o} and L{\'a}szl{\'o} Tam{\'a}si and G. Szegedi and Yehuda Shoenfeld and P. Solt{\'e}sz",
year = "2007",
month = "6",
doi = "10.1196/annals.1422.036",
language = "English",
isbn = "157331708X",
volume = "1108",
series = "Annals of the New York Academy of Sciences",
pages = "349--358",
booktitle = "Annals of the New York Academy of Sciences",

}

TY - GEN

T1 - Accelerated atherosclerosis in rheumatoid arthritis

AU - Szekanecz, Z.

AU - Kerekes, G.

AU - Dér, H.

AU - Sándor, Zsuzsa

AU - Szabó, Z.

AU - Végvári, A.

AU - Simkovics, Enikö

AU - Soós, Lilla

AU - Szentpétery, Ágnes

AU - Besenyei, Timea

AU - Szűcs, G.

AU - Szántó, S.

AU - Tamási, László

AU - Szegedi, G.

AU - Shoenfeld, Yehuda

AU - Soltész, P.

PY - 2007/6

Y1 - 2007/6

N2 - Cardiovascular disease is a leading cause of mortality in rheumatoid arthritis (RA). Endothelial dysfunction often precedes manifest atherosclerosis. Both traditional, Framingham risk factors and inflammation-associated factors are involved in RA-associated atherosclerosis. Among imaging techniques, the early determination of common carotid intima-media thickness (ccIMT), flow-mediated vasodilation (FMD), and nitroglycerine-mediated vasodilation (NMD) may be useful to determine atherosclerosis and endothelial dysfunction.We and others found increased ccIMT and impaired FMD in RA patients. Among immunological and metabolic laboratory markers, anticyclic citrullinated peptide (anti-CCP) antibodies, IgM rheumatoid factor, circulating immune complexes, pro-inflammatory cytokines including tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), Th0/Th1Tcells, homocysteine, dyslipidemia, decreased folate and vitamin B12 production, and impaired paraoxonase activity may all be involved in the development of vascular disease in RA. The early diagnosis of endothelial dysfunction and atherosclerosis, active immunosuppressive treatment, the use of drugs that control atherosclerosis, changes in sedentary lifestyle, and the close follow-up of RA patients may help to minimize cardiovascular risk in these individuals.

AB - Cardiovascular disease is a leading cause of mortality in rheumatoid arthritis (RA). Endothelial dysfunction often precedes manifest atherosclerosis. Both traditional, Framingham risk factors and inflammation-associated factors are involved in RA-associated atherosclerosis. Among imaging techniques, the early determination of common carotid intima-media thickness (ccIMT), flow-mediated vasodilation (FMD), and nitroglycerine-mediated vasodilation (NMD) may be useful to determine atherosclerosis and endothelial dysfunction.We and others found increased ccIMT and impaired FMD in RA patients. Among immunological and metabolic laboratory markers, anticyclic citrullinated peptide (anti-CCP) antibodies, IgM rheumatoid factor, circulating immune complexes, pro-inflammatory cytokines including tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), Th0/Th1Tcells, homocysteine, dyslipidemia, decreased folate and vitamin B12 production, and impaired paraoxonase activity may all be involved in the development of vascular disease in RA. The early diagnosis of endothelial dysfunction and atherosclerosis, active immunosuppressive treatment, the use of drugs that control atherosclerosis, changes in sedentary lifestyle, and the close follow-up of RA patients may help to minimize cardiovascular risk in these individuals.

KW - Atherosclerosis

KW - Endothelial dysfunction

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=34948903757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34948903757&partnerID=8YFLogxK

U2 - 10.1196/annals.1422.036

DO - 10.1196/annals.1422.036

M3 - Conference contribution

C2 - 17893998

AN - SCOPUS:34948903757

SN - 157331708X

SN - 9781573317085

VL - 1108

T3 - Annals of the New York Academy of Sciences

SP - 349

EP - 358

BT - Annals of the New York Academy of Sciences

ER -